Skip to content

FEATUring ouR

Sync product line

Balancing daily responsibilities and taking time for self-care can be a struggle; sometimes, you need a little help relaxing your mind and body. The SYNCTM portfolio includes an array of smoke-free all-natural products that come in different potencies and flavours. We’ve elevated our select flavoured products with similar tasting terpenes that enhance user experience. Terpenes are naturally occurring compounds found in certain plants that have therapeutic effects. Get in SYNC and harmonize your wellness routines.

SYNC 25
NATURAL CBD OIL

Our newly formulated SYNCTM 25 CBD oil uses whole-flower extracted cannabis grown in British Columbia, and 100% organic coconut-derived carrier oil.

SYNC NANO
FAST-ACTION SPRAYS

SYNCTM Nano Fast-Action Sprays use nanoemulsion technology to achieve faster and more predictable effects. 

FLAVOURED THC & CBD CANNABIS OILS

We use all-natural ingredients in our select flavoured products and plant-based terpenes that enhance user experience.

MEDICAL CANNABIS

Prescriptions and Patient Registration

Do you have a prescription for medical cannabis and want to get it filled? Register as a patient with Emerald in three simple steps and access our excellent selection of medical cannabis products. If you don’t have a prescription, apply for online consultation with a certified health care practitioner. 

INVESTOR RELATIONS

Emerald Health Therapeutics, Inc. is publicly traded on the TSXV (EMH) and the OTCQX (EMHTF). Visit our Investors page for the latest news releases, financial reports and more – everything you need to know to invest with confidence.

CONNECT WITH OUR COMMUNITY

Rebecca Wong

Vice President, Quality and Regulatory Affairs

Ms. Wong has more than 25 years of managerial experience in quality assurance and quality control spanning research, preclinical, clinical, and commercial phases for pharmaceuticals, combination products, biologicals and medical devices. Before joining Emerald, she was the Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), where she was the head of quality assurance, validation, compliance auditing, document management, and GxP training departments. Ms. Wong previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Specializing in microbiology, she earned a BSc from the University of Alberta.

Jenn Hepburn

Chief Financial Officer

Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.

RIAZ BANDALI

President & Chief Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.